Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the effect of UT-15C sustained release (SR) on exercise capacity compared to placebo (as measured by the change in 6-Minute Walk distance from Baseline to Week 12) in subjects with PAH who are not currently receiving endothelin receptor antagonist (ERA), phosphodiesterase (PDE)-5 inhibitor, prostacyclin therapy, or any combination. The change in 6-Minute Walk distance will be evaluated primarily for subjects with access to 0.25 mg tablets at the time of randimization, and secondarily for the overall population.
Critère d'inclusion
- Idiopathic or familial pulmonary arterial hypertension (PAH), including PAH associated with:,1) Appetite suppressant/toxin use, or 2) Repaired congenital systemic-to-pulmonary shunts (repaired ≥ 5 years), or 3) Collagen Vascular Disease (CVD), or 4) Human Immunodeficiency virus (HIV)